Homoarginine in the shadow of asymmetric dimethylarginine: from nitric oxide to cardiovascular disease

[1]  F. Kronenberg,et al.  Serum concentrations of L-arginine and L-homoarginine in male patients with intermittent claudication: a cross-sectional and prospective investigation in the CAVASIC Study. , 2015, Atherosclerosis.

[2]  T. Psaltopoulou,et al.  Oxidative Stress and Early Atherosclerosis: Novel Antioxidant Treatment , 2015, Cardiovascular Drugs and Therapy.

[3]  R. Wachter,et al.  Associations of methylarginines and homoarginine with diastolic dysfunction and cardiovascular risk factors in patients with preserved left ventricular ejection fraction. , 2014, Journal of cardiac failure.

[4]  C. Ayers,et al.  Homoarginine and Cardiovascular Outcome in the Population-Based Dallas Heart Study , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[5]  D. Tsikas,et al.  Plasma homoarginine (hArg) and asymmetric dimethylarginine (ADMA) in patients with rheumatoid arthritis: is homoarginine a cardiovascular corrective in rheumatoid arthritis, an anti-ADMA? , 2014, International journal of cardiology.

[6]  D. Tsikas,et al.  Do homoarginine and asymmetric dimethylarginine act antagonistically in the cardiovascular system? , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[7]  D. Tsikas,et al.  Homoarginine and 3-nitrotyrosine in patients with takotsubo cardiomyopathy. , 2014, International journal of cardiology.

[8]  H. Völzke,et al.  Incidence of All-Cause and Cardiovascular Mortality Predicted by Symmetric Dimethylarginine in the Population-Based Study of Health in Pomerania , 2013, PloS one.

[9]  S. Bode-Böger,et al.  Opposite Associations of Plasma Homoarginine and Ornithine with Arginine in Healthy Children and Adolescents , 2013, International journal of molecular sciences.

[10]  N. Frey,et al.  Homoarginine--an independent marker of mortality in heart failure. , 2013, International journal of cardiology.

[11]  C. Gerloff,et al.  Homoarginine Levels Are Regulated by L-Arginine: Glycine Amidinotransferase and Affect Stroke Outcome Results From Human and Murine Studies , 2013, Circulation.

[12]  T. Michel.  R is for arginine: metabolism of arginine takes off again, in new directions. , 2013, Circulation.

[13]  T. Lehtimäki,et al.  Genome-Wide Association Study Identifies 3 Genomic Loci Significantly Associated With Serum Levels of Homoarginine: The AtheroRemo Consortium , 2013, Circulation. Cardiovascular genetics.

[14]  J. Dekker,et al.  L-Homoarginine and L-arginine are antagonistically related to blood pressure in an elderly population: the Hoorn study , 2013, Journal of hypertension.

[15]  F. Kronenberg,et al.  Homoarginine and Progression of Chronic Kidney Disease: Results from the Mild to Moderate Kidney Disease Study , 2013, PloS one.

[16]  H. Blom,et al.  Promiscuous activity of arginine:glycine amidinotransferase is responsible for the synthesis of the novel cardiovascular risk factor homoarginine , 2012, FEBS letters.

[17]  C. Stefanadis,et al.  Pathophysiology of atherosclerosis: the role of inflammation. , 2011, Current pharmaceutical design.

[18]  C. Tsioufis,et al.  Methionine-induced homocysteinemia impairs endothelial function in hypertensives: the role of asymmetrical dimethylarginine and antioxidant vitamins. , 2011, American journal of hypertension.

[19]  W. März,et al.  Low homoarginine concentration is a novel risk factor for heart disease , 2011, Heart.

[20]  W. März,et al.  Low Serum Homoarginine Is a Novel Risk Factor for Fatal Strokes in Patients Undergoing Coronary Angiography , 2011, Stroke.

[21]  W. März,et al.  Homoarginine, Cardiovascular Risk, and Mortality , 2010, Circulation.

[22]  C. Stefanadis,et al.  Endothelial dysfunction: potential clinical implications. , 2010, Minerva medica.

[23]  V. Chopra,et al.  Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography , 2009, Coronary artery disease.

[24]  T. Laitinen,et al.  Serum L-homoarginine concentration is elevated during normal pregnancy and is related to flow-mediated vasodilatation. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[25]  C. Björkelund,et al.  Asymmetric Dimethylarginine Independently Predicts Fatal and Nonfatal Myocardial Infarction and Stroke in Women: 24-Year Follow-Up of the Population Study of Women in Gothenburg , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[26]  H. Valantine,et al.  Asymmetric Dimethylarginine and Cardiac Allograft Vasculopathy Progression: Modulation by Sirolimus , 2008, Transplantation.

[27]  T. Laitinen,et al.  Subtle changes in ADMA and l‐arginine concentrations in normal pregnancies are unlikely to account for pregnancy‐related increased flow‐mediated dilatation , 2008, Clinical physiology and functional imaging.

[28]  S. Hazen,et al.  Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial Infarction , 2007, Circulation.

[29]  O. Ozeke,et al.  Asymmetric dimethylarginine plasma concentrations and L-arginine/asymmetric dimethylarginine ratio in patients with slow coronary flow , 2007, Coronary artery disease.

[30]  T. Laitinen,et al.  Brachial Artery Flow-Mediated Dilation and Asymmetrical Dimethylarginine in the Cardiovascular Risk in Young Finns Study , 2007, Circulation.

[31]  D. Tsikas,et al.  Asymmetric dimethylarginine (ADMA)--a modulator of nociception in opiate tolerance and addiction? , 2007, Nitric oxide : biology and chemistry.

[32]  T. Lüscher,et al.  Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia. , 2007, Atherosclerosis.

[33]  T. Imaizumi,et al.  Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study. , 2007, Atherosclerosis.

[34]  W. März,et al.  Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). , 2007, Clinical chemistry.

[35]  M. Wolzt,et al.  Asymmetric Dimethylarginine Predicts Major Adverse Cardiovascular Events in Patients With Advanced Peripheral Artery Disease , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[36]  C. Stefanadis,et al.  Asymmetrical dimethylarginine regulates endothelial function in methionine-induced but not in chronic homocystinemia in humans: effect of oxidative stress and proinflammatory cytokines. , 2006, The American journal of clinical nutrition.

[37]  W. Daniel,et al.  Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. , 2006, American heart journal.

[38]  D. Tsikas,et al.  Asymmetric dimethylarginine (ADMA) and the risk for coronary heart disease: the multicenter CARDIAC study , 2006, European Journal of Clinical Pharmacology.

[39]  J. Chin-Dusting,et al.  AMINO ACIDS, ARGINASE AND NITRIC OXIDE IN VASCULAR HEALTH , 2006, Clinical and experimental pharmacology & physiology.

[40]  J. Leiper,et al.  The DDAH-ADMA-NOS Pathway , 2005, Therapeutic drug monitoring.

[41]  R. Schnabel,et al.  Asymmetric Dimethylarginine and the Risk of Cardiovascular Events and Death in Patients With Coronary Artery Disease: Results from the AtheroGene Study , 2005, Circulation research.

[42]  T. Meinertz,et al.  Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. , 2005, European heart journal.

[43]  C. Zoccali,et al.  Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. , 2005, Journal of the American College of Cardiology.

[44]  R. Böger.  Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials , 2005, Vascular medicine.

[45]  N. Usui,et al.  Platelet size deviation width, platelet large cell ratio, and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia , 2005, British journal of haematology.

[46]  K. Channon,et al.  Systemic Regulation of Vascular NAD(P)H Oxidase Activity and Nox Isoform Expression in Human Arteries and Veins , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[47]  Shing‐Jong Lin,et al.  Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. , 2003, European heart journal.

[48]  M. Charng,et al.  Asymmetrical dimethylarginine: A novel risk factor for coronary artery disease , 2003, Clinical cardiology.

[49]  R. Böger.  The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. , 2003, Cardiovascular research.

[50]  P. Vallance,et al.  Asymmetric Dimethylarginine Causes Hypertension and Cardiac Dysfunction in Humans and Is Actively Metabolized by Dimethylarginine Dimethylaminohydrolase , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[51]  Y. Aizawa,et al.  Significance of asymmetric dimethylarginine (ADMA) concentrations during coronary circulation in patients with vasospastic angina. , 2003, Circulation journal : official journal of the Japanese Circulation Society.

[52]  Amir Lerman,et al.  Endothelial Dysfunction: A Marker of Atherosclerotic Risk , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[53]  T. Lehtimäki,et al.  Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine , 2001, The Lancet.

[54]  C. Zoccali,et al.  Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study , 2001, The Lancet.

[55]  S. Homma,et al.  Acute Elevations of Plasma Asymmetric Dimethylarginine and Impaired Endothelial Function in Response to a High-Fat Meal in Patients With Type 2 Diabetes , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[56]  D. Tsikas,et al.  Endogenous nitric oxide synthase inhibitors are responsible for the L‐arginine paradox , 2000, FEBS letters.

[57]  D. Tsikas,et al.  LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. , 2000, Circulation research.

[58]  D. Tsikas,et al.  Assessment of nitric oxide synthase activity in vitro and in vivo by gas chromatography-mass spectrometry. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[59]  K. Okumura,et al.  Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension : modulation of nitric oxide synthesis by salt intake. , 2000, Circulation.

[60]  Ian G. Charles,et al.  Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. , 1999, The Biochemical journal.

[61]  P. Tsao,et al.  Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. , 1999, Circulation.

[62]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[63]  J. Cooke,et al.  Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. , 1999, Circulation.

[64]  W. A. Aue,et al.  Filterless, full spectral range, compound-specific detection in dual-channel photometry , 1996 .

[65]  P. Sanders,et al.  Role of nitric oxide synthesis in salt-sensitive hypertension in Dahl/Rapp rats. , 1993, Hypertension.

[66]  S. Moncada,et al.  Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure , 1992, The Lancet.

[67]  S. Moncada,et al.  An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[68]  M. Goniewicz,et al.  Tobacco smoking decreases plasma concentration of the emerging cardiovascular risk marker, L-homoarginine. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[69]  F. Grimminger,et al.  Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. , 2007, American journal of physiology. Lung cellular and molecular physiology.